Opinion
Video
Panelists discuss how managing patients with mild cognitive impairment using amyloid-targeting therapies faces significant barriers including limited healthcare infrastructure for complex diagnostic testing and monitoring, insufficient insurance coverage and high out-of-pocket costs, challenges in patient selection and risk stratification, logistical hurdles of regular infusions and imaging, shortage of specialists in many regions, and the need for comprehensive patient education about realistic treatment expectations.
Video content above is prompted by the following: